Moreover, restoring or stabilizing the transcriptional–electrical program pharmacologically (e.g., through SKCa/IKCa activators or FOXO3-inducing agents) may offer therapeutic potential in cardiovascular disease, cancer, or tissue repair. The gene discussed is FOXO3; the disease is cardiovascular disorder.